1 / 54

بسم الله الرحمن الرحيم

بسم الله الرحمن الرحيم. Community-Acquired Pneumonia. B.Hajikarim ZUMS 2010. Importance of CAP. A major cause of death globally Death rate due to pneumonia: 75000 High incidence & mortality patients per year: 4,000,000 Mortality Rate: 2-30% High rate of hospitalization (600,000/15%).

donat
Download Presentation

بسم الله الرحمن الرحيم

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. بسم الله الرحمن الرحيم

  2. Community-Acquired Pneumonia B.Hajikarim ZUMS 2010

  3. Importance of CAP • A major cause of death globally • Death rate due to pneumonia: 75000 • High incidence & mortality • patients per year: 4,000,000 • Mortality Rate: 2-30% • High rate of hospitalization • (600,000/15%)

  4. CAP In The Past DECADE Dramatic changes in the etiology (Emerging pathogens) Growth of antimicrobial resistance Dramatic changes in the diagnosis & management

  5. Pathogenesis • Defense mechanisms: • Filtering system • cough, sneezing, & reflex glottis • ciliated cells • Clearing system • Macrophages • T & B lymphocytes

  6. Transmission routes: • Aspiration of oropharyngial colonization • Inhalation of infectious aerosols • Hematogenous dissemination • Direct inoculation

  7. ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA • Pathogen not defined in as many as 50 % patients even with extensive diagnostic testing • S. pneumonia is the leading cause of CAP • H. influenzae ( type B), S. aureus, and gram (-) bacteria each account for 3 to 10 % • Staph aureus CAP is usually seen in the elderly and as post-influenza pneumonia

  8. ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA • P. aeruginosa causes CAP in neutropenia, cystic fibrosis, HIV infection & bronchiectasis • N. meningitidis, M. catarrhalis & S. pyogenes can occasionally cause CAP • Anaerobic organisms are implicated in aspiration pneumonia and lung abscess • MRSA, M. tuberculosis & certain viral agents are common in nursing-home patients

  9. Community acquired pneumonia (CAP) • Definition: • Acute signs & symptoms (respiratory or nonrespiratory) • New radiographic infiltrate • Acquisition of infection from outside the confines of a hospital

  10. Clinical approach to pneumonia • History • Physical examination • Age • Epidemiologic data • Predisposing conditions

  11. History • Typical or atypical pneumonia syndromes • Host consideration: • Neonates (no fever, mild & prolonged symptoms) • Young infants (viral pneumonia with respiratory distress & fever +/- sepsis) • Elderly (Changes in eating habit or mental function, minimum of respiratory symptoms)

  12. History • Special considerations by organism: • M.TB & fungal pneumonia (gradual onset) • Mycoplasma & Chlamydia pneumonia (protracted cough, minimum sputum) • Legionnaires’ disease (relative bradycardia, renal, liver. Mental & GI abnormalities)

  13. Physical examination • Signs of nonpneumonic infection • Signs of pleural effusion • Signs of anomalies lead to intrapulmonary process(DVT, clubbing, …) • Host considerations(very young & very old patients ,immune status)

  14. Epidemiologic data • Family history(RSV, Mycoplasma.p, Influenza) • Travel history • Unusual contact(with animal, birds, excavation) • Seasonal & geographic differences • Patients living circumstances

  15. Age • Newborn: Viruses (CMV,Rubella,HSV) Bacteria (GBS) • 1 - 3 m:Viruses (RSV, influenza & Para.inf) Bacteria (Chlamidia.tracho, Bordetella) • 3m -5Y:Viruses (RSV, Para.in, Adeno, Influ) Bacteria (S.Pneu, H.inf, Chla.P, Myco.P)

  16. Age • 5 - 18Y: Viruses( Para.inf, Influ, Adeno) Bacteria (Myco, Chla, Pneu) • 18 -65Y: Viruses (Para.inf, Influ, Adeno) Bacteria(Myco.P, Chla.P, S.Pneu) • Over 65Y:Bacteria (S.Pneumo, H.inf, gr neg,Staph, mora.C,Legio.P Viruses

  17. Predisposing conditions • In alcoholics: S.pneumonia, K.pneumonia, H.Influenza, M.Tuberculosis • Aspiration Of URT secretions • Chronic obstructive pulmonary disease: H.influenza, S.pneumonia, Moraxella catarralis • Cystic fibrosis: Staphylococcal & Pseudomonas infection • Post influenza bacterial pneumonias

  18. Predisposing conditions • Immune status (including HIV/AIDS): • Hypogammaglubolinemia:Encapsulated bacteria • Sever neutropenia: Pseudomonas, Staphylococcal & Fungal inf. • HIV & AIDS :Consider CD4 count • Corticosteroid therapy:M.TB, Nocardial infections

  19. Clinical approach to pneumonia(Review) • History • Physical examination • Age • Epidemiologic data • Predisposing conditions

  20. Diagnostic evaluation • Baseline assessment • Outpatient assessment • Inpatient assessment

  21. Baseline assessment • Chest X.ray useful for: • Diagnosis of pneumonia • Diagnosis of etiologic agents • Location of infiltration • Cavitations • Volume loss • Pleural effusion • Mediastinal adenopathy

  22. Baseline assessment • Chest X.ray useful for: • Detecting associated conditions • Follow up (rapid changes over 8-36 h) • Patients clinically improving(gradually or even longer clearing) • Patients not improving(bronchial obstruction, super infection, associated effusion, abscess)

  23. Pneumococcal pneumonia: lobar consolidation affecting both lungs. An air bronchogram is easily seen in the left middle zone

  24. Mycoplasma pneumonia: patchy consolidation in several areas in both lungs

  25. Staphylococcal pneumonia: pneumatoceles (arrowed) in right middle and lower lobes and in left lower lobe (infant) Posteroanterior lateral

  26. Pulmonary tuberculosis: consolidation & cavitation of left upper lobe

  27. Pulmonary tuberculosis: extensive consolidation of the left lung with partial collapse. Less severe changes are seen on the right

  28. Tuberculosis of mediastinal glands: widening of superior mediastinum by enlarged right paratrachael lymph nodes

  29. Tuberculous pleurisy: small right pleural effusion

  30. Lung abscess: abscess cavity in lower lobe of right lung. posteroanterior lateral

  31. Chest x-ray • False negative results • High resolution CT (HRCT) is more sensitive for the evaluation of: • interstitial disease • bilateral disease • cavitations • empyema • hilar adenopathy

  32. Outpatient assessment • Sputum stains: • gram staining of sputum • Appearance • Adequacy • Unsuspected gram negative organisms • Acid fast smear & culture

  33. Gram's stain of expectorated sputum • Sensitivity and specificity vary widely depending on the criteria used to define a "positive” stain • > 25 neutrophils and < 10 squamous epithelial cells per low power field • Cytologic screening criteria not evaluated for Legionella, mycobacteria or viral infections • Direct staining of sputum may be diagnostic for Mycobacterium sp., endemic fungi, Legionella sp. (DFA stain) & P. carinii

  34. Sputum Gram stain

  35. Sputum Gram Stain

  36. Inpatient assessment Recovery of the organism • Obtaining of different diagnostic specimens before treatment: • Blood culture • A good sputum for smear & culture • Aspiration & culture of pleural fluid • Other body secretion cultures

  37. Invasive diagnostic techniques • Transtracheal aspiration • Bronchoscopy with a protected brush catheter • Bronchoalveolar lavage with or without balloon protection • Direct needle aspiration of the lung

  38. Diagnostic evaluation(Review) • Baseline assessment • Outpatient assessment • Inpatient assessment

  39. Management • Choose the Environment of management By: Pneumonia Severity Index.

  40. PNEUMONIA SEVERITY INDEX (PSI) CLINICAL PREDICTION RULE • The PSI rule stratified adults with radiographic evidence of CAP into five classes for risk of death from all causes within 30 days of presentation • Predictor Variables • age • sex • comorbid illnesses • physical findings • selected laboratory findings • The PSI is applied in two steps

  41. PNEUMONIA SEVERITY INDEX

  42. Step 2 of prediction rule • Age (age years) • Coexisting illnesses (10 – 80) • Physical examination findings (10-65) • Laboratory and radiographic findings (10 – 110)

  43. STRATIFICATION OF RISK SCORE

  44. SEVERE COMMUNITY-ACQUIRED PNEUMONIA There is no universally accepted definition of severe CAP: ATS definition: • Requirement for mechanical ventilation • Requirement for vasopressors for more than 4 h • SBP < 90 mmHg • Severe respiratory failure defined by a Pao2/Flo2 ratio <250 • Multilobar involvement

  45. Management Antibiotic choices

  46. outpatient < 60 yrs • Amoxicillin (500mg TDS) • Macrolides Erythromycin (500mg Qid) Azithromycin (500mg then 250mg daily) Clarithromycin (500mg BD) • Doxycycline (100mg BID) • Flouroquinolone (IDSA)

  47. outpatient 60 yrs or > or adult with preexisisting disease 1. beta-lactam ( cefpodoxime, high dose amoxicillin, amox-clav., ceftrioxone) PLUS macrolide or doxycycline 2. antipneumococcal quinolone (only IDSA)

  48. Pathogen Resistance in CAP • Three specific pathogen: H.inf, S.pneu, M.cata • Linear increase in the magnitude of ampicillin resistance with: H.inf=33%, M.cata=100% • High prevalence of penicillin resistance with S.pneu=35% • Non-betalactam resistance with S.pneu: Macrolides=26% clindamycin=9% Tetracycline=16% Chloramphenicole=8% TMP-SMZ=30% Fluoroquinolones=0.2%

  49. DURATION OF TREATMENT a) coexisting illness and/or bacteremia b) the severity of illness at the onset of antibiotic therapy c) the subsequent hospital courseorganism duration of treatment S. pneumoniae approximately 7 to 10 days M. pneumoniae 10 to 14 days C. pneumoniae 10 to 14 days Legionnella pneumonia 14 days 21 days if immunocompromised

More Related